Showing 1 to 12 of 28 results
Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression
A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.
Huntington's Disease Treatment Shows 75% Slowdown in Clinical Progression
A new gene therapy has demonstrated a 75% slowdown of Huntington's disease progression in a clinical trial, offering a potential life-extending treatment for those affected.
Progress
48% Bias Score
Artificial Sweeteners Linked to Accelerated Cognitive Decline in Middle-Aged Adults
A study of almost 13,000 Brazilian adults found a correlation between high artificial sweetener consumption and a 62% faster decline in cognitive skills, particularly in those with diabetes, but not in participants over 60.
Artificial Sweeteners Linked to Accelerated Cognitive Decline in Middle-Aged Adults
A study of almost 13,000 Brazilian adults found a correlation between high artificial sweetener consumption and a 62% faster decline in cognitive skills, particularly in those with diabetes, but not in participants over 60.
Progress
16% Bias Score
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A French clinical trial is testing photobiostimulation to treat Parkinson's disease by targeting mitochondria in deep brain neurons; early results show symptom improvement in three of seven patients with continuous stimulation.
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A French clinical trial is testing photobiostimulation to treat Parkinson's disease by targeting mitochondria in deep brain neurons; early results show symptom improvement in three of seven patients with continuous stimulation.
Progress
40% Bias Score
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
EMA Reverses Alzheimer's Drug Block, Approves Donanemab Under Strict Protocols
The European Medicines Agency (EMA) reversed its decision to block Donanemab, a new Alzheimer's treatment, approving it for early-stage patients with at most one copy of a specific gene under strict safety protocols after initially deeming the risks outweighed the benefits; Donanemab slows Alzheimer...
Progress
40% Bias Score
Ozzy Osbourne's Death Highlights Parkinson's Disease Challenges
Rock legend Ozzy Osbourne died at 76 this week from complications of Parkinson's disease, a neurological disorder affecting 10 million globally, highlighting the disease's progressive nature and lack of a cure.
Ozzy Osbourne's Death Highlights Parkinson's Disease Challenges
Rock legend Ozzy Osbourne died at 76 this week from complications of Parkinson's disease, a neurological disorder affecting 10 million globally, highlighting the disease's progressive nature and lack of a cure.
Progress
16% Bias Score
Myasthenia Gravis: Delayed Diagnosis, Economic Burden, and Future Research Needs
Myasthenia gravis (MG), a chronic autoimmune neuromuscular disease affecting approximately 20 per 100,000 people globally, causes muscle weakness and fatigue; delayed diagnosis significantly impacts patients' quality of life and healthcare resource utilization, imposing substantial economic burdens ...
Myasthenia Gravis: Delayed Diagnosis, Economic Burden, and Future Research Needs
Myasthenia gravis (MG), a chronic autoimmune neuromuscular disease affecting approximately 20 per 100,000 people globally, causes muscle weakness and fatigue; delayed diagnosis significantly impacts patients' quality of life and healthcare resource utilization, imposing substantial economic burdens ...
Progress
20% Bias Score
Study Links Artificial Sweetener Consumption to Accelerated Cognitive Decline
A new study of over 13,000 Brazilians revealed a link between high artificial sweetener consumption and faster cognitive decline, particularly in working memory and verbal fluency, with the highest consumers experiencing a decline equivalent to 1.6 years of brain aging.
Study Links Artificial Sweetener Consumption to Accelerated Cognitive Decline
A new study of over 13,000 Brazilians revealed a link between high artificial sweetener consumption and faster cognitive decline, particularly in working memory and verbal fluency, with the highest consumers experiencing a decline equivalent to 1.6 years of brain aging.
Progress
36% Bias Score
Traumatic Brain Injury Significantly Raises Malignant Brain Tumor Risk
A study of 150,000 adults found those with moderate to severe traumatic brain injuries had a significantly higher risk of developing malignant brain tumors within 3-5 years compared to those with mild injuries or no history of TBI, prompting calls for long-term patient monitoring.
Traumatic Brain Injury Significantly Raises Malignant Brain Tumor Risk
A study of 150,000 adults found those with moderate to severe traumatic brain injuries had a significantly higher risk of developing malignant brain tumors within 3-5 years compared to those with mild injuries or no history of TBI, prompting calls for long-term patient monitoring.
Progress
48% Bias Score
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A preliminary clinical trial in France is evaluating photobiostimulation to treat Parkinson's disease; initial results from seven patients show symptom stabilization in three with continuous light stimulation, offering a new non-invasive treatment approach.
French Trial Shows Promise for Photobiostimulation in Parkinson's Treatment
A preliminary clinical trial in France is evaluating photobiostimulation to treat Parkinson's disease; initial results from seven patients show symptom stabilization in three with continuous light stimulation, offering a new non-invasive treatment approach.
Progress
44% Bias Score
Ozzy Osbourne's Death Highlights Parkinson's Disease Impact
Rock musician Ozzy Osbourne died at 76 after a five-year battle with Parkinson's disease, a neurological disorder affecting movement control and impacting approximately 10 million people globally.
Ozzy Osbourne's Death Highlights Parkinson's Disease Impact
Rock musician Ozzy Osbourne died at 76 after a five-year battle with Parkinson's disease, a neurological disorder affecting movement control and impacting approximately 10 million people globally.
Progress
24% Bias Score
Ozzy Osbourne's Death Highlights Parkinson's Disease Prevalence
Ozzy Osbourne, Black Sabbath's lead singer, died at 76; his 2019 Parkinson's diagnosis highlights the disease's increasing prevalence (affecting 1.1 million Americans, projected to reach 1.2 million by 2030), lack of cure, and available treatments for symptom management.
Ozzy Osbourne's Death Highlights Parkinson's Disease Prevalence
Ozzy Osbourne, Black Sabbath's lead singer, died at 76; his 2019 Parkinson's diagnosis highlights the disease's increasing prevalence (affecting 1.1 million Americans, projected to reach 1.2 million by 2030), lack of cure, and available treatments for symptom management.
Progress
16% Bias Score
Saxony-Anhalt Hospitals Form Network to Improve Stroke Treatment
A new network of hospitals in northern Saxony-Anhalt, Germany, aims to improve stroke treatment by standardizing care, using telemedicine, and deploying a mobile intervention team to reduce intervention times and improve patient outcomes, addressing the high number of strokes in the state's aging po...
Saxony-Anhalt Hospitals Form Network to Improve Stroke Treatment
A new network of hospitals in northern Saxony-Anhalt, Germany, aims to improve stroke treatment by standardizing care, using telemedicine, and deploying a mobile intervention team to reduce intervention times and improve patient outcomes, addressing the high number of strokes in the state's aging po...
Progress
36% Bias Score
Showing 1 to 12 of 28 results